Market Research on Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.
To access full report with TOC, please visit Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
- The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)
- The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
- Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
- Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA Affimed GmbH arGEN-X BV Bayer AG Boehringer Ingelheim GmbH Celgene Corporation CerRx, Inc. Chipscreen Biosciences Ltd CSPC Pharmaceutical Group Limited Eisai Co., Ltd. Genosco Incyte Corporation Japan Tobacco Inc. Johnson & Johnson Mundipharma International Ltd Ono Pharmaceutical Co., Ltd. Onxeo SA Pfizer Inc. Pharma Mar, S.A. Portola Pharmaceuticals, Inc. Rhizen Pharmaceuticals S.A. Seattle Genetics, Inc. Solasia Pharma K.K. Spectrum Pharmaceuticals, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 21:53
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home